A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions

ObesityOverweight

Interventions

DRUG

Eloralintide

Administered subcutaneously (SC)

DRUG

Placebo

Administered SC

Trial Locations (1)

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY